-transparent.png){kind=logo}
A randomized cross-over trial of dexamethasone (10 mg I.V. before therapy, and 4 mg I.V. q 4 h X 6 doses) vs. placebo as antiemetic therapy was conducted in 19 patients receiving high-dose cisplatin. Sixteen patients and 32 treatment courses were fully evaluable. There was no significant difference between regimens in the number of emesis-free patients or the number of emetic episodes, though the duration of nausea symptoms may have been reduced. We conclude that dexamethasone as used in our trial is not an effective antiemetic in patients receiving cisplatin.
Related Publications
B W Dana, and
E C Everts, and
D Dickinson
January 1987,
Cancer chemotherapy and pharmacology,
B W Dana, and
E C Everts, and
D Dickinson
March 1989,
Japanese journal of clinical oncology,
B W Dana, and
E C Everts, and
D Dickinson
June 1996,
Japanese journal of clinical oncology,
B W Dana, and
E C Everts, and
D Dickinson
August 1991,
Lancet (London, England),
B W Dana, and
E C Everts, and
D Dickinson
October 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
B W Dana, and
E C Everts, and
D Dickinson
January 2004,
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
B W Dana, and
E C Everts, and
D Dickinson
July 1992,
Lancet (London, England),
B W Dana, and
E C Everts, and
D Dickinson
May 1998,
Gan to kagaku ryoho. Cancer & chemotherapy,
B W Dana, and
E C Everts, and
D Dickinson
January 1991,
Acta oncologica (Stockholm, Sweden),
B W Dana, and
E C Everts, and
D Dickinson
January 1991,
Oncology,
